A recent study suggests that patients who discontinue new weight-loss injections like Mounjaro or Wegovy tend to recover lost weight far faster than those who halt traditional diet and exercise plans.
Published data in a prominent health publication demonstrates that while obese individuals frequently drop a large proportion of their body weight while on the medication, the mass is regained at an average rate of nearly a kilo each month after stopping.
"People using these drugs should be informed of the danger of quick weight regain when the therapy ends," cautioned expert Dr. Susan Jebb.
This pace of recovery implies a return to pre-treatment mass within about a year and a half.
Weighing Approaches
The study, which examined 37 of studies involving thousands of participants, contrasted the results of GLP-1 agonists with other pills.
Researchers note that people who shed pounds through diet and exercise usually have a less rapid weight regain—perhaps 100 grams monthly—after stopping.
Understanding the Fast Rebound
Doctors propose the way of the injections is key to understanding the heightened rebound.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing the hormone concentrations far above than normal may cause the system to produce less of its own natural hormone, and could reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement leads to hunger is unsuppressed, making overeating far more likely."
A Lifelong Condition?
Medical guidelines suggest the jabs for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Many experts say that, given the likelihood of relapse, the treatment might need to be long-term.
This view is reinforced by pharmaceutical companies, who say that the findings "emphasize the persistent character of excess weight," similar to managing diseases like hypertension.
Patient Testimonies
Users who have come off the medication report a sudden return of cravings.
"It was like a trigger flipping and I was suddenly ravenous," said one woman.
This difficulty is exacerbated if users have not developed permanent dietary or behavioural modifications during therapy.
Significant Adoption
Survey data suggest that millions of people in the UK have tried these injections in the last 12 months, with demand remaining high.
- Adoption is more common among females compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, researchers stress that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone fix and long-term success hinges on integrated behavioural management.
